947669-86-5
基本信息
AKIIPHDGVCFVCC-UHFFFAOYSA-N
ethyl 4-[4-[methyl-[(3-pyridin-4-ylphenyl)methyl]carbamoyl]oxyphenyl]benzoate
4'-[[[Methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-[1,1'-biphenyl]-4-carboxylic acid ethyl ester
物理化学性质
| 沸点 | 630.9±55.0 °C(Predicted) |
| 密度 | 1?+-.0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMF: 25 mg/ml; DMF:PBS(pH7.2) (1:2): 0.3 mg/ml; DMSO: 15 mg/ml; Ethanol: 0.1 mg/ml |
| 酸度系数(pKa) | 5.18±0.26(Predicted) |
| 形态 | 结晶固体 |
| 颜色 | White to off-white |
常见问题列表
IC50: 120 nM (Ces3), 100 nM (Ces1f).
Ces3 and Ces1f are endoplasmic reticulum glycoproteins that have been previously associated with adipocyte lipolysis. WWL113 inhibits mouse recombinant Ces1, Ces1c, and ABHD6 at 10 μM.
WWL113 (1 μM) significantly increases UCP1 protein expression in brown adipocytes.
WWL113 has a partial, statistically significant inhibitory effect on blocking the buildup of PGE2.
WWL113 (30 mg/kg, orally once a day) results in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance.
WWL113 ameliorates obesity-diabetes in mice.
| Animal Model: | Eight-week-old db/db mice (n = 10 per group). |
| Dosage: | 30 mg/kg. |
| Administration: | Orally once a day for 3 weeks. |
| Result: | Corrected multiple features of metabolic syndrome in db/db mice. |